Abstract
In a recent issue of PharmacoEconomics, Liljas discusses how to incorporate indirect costs into a cost-effectiveness analysis. He argues that the human capital–cost approach is the best available method for estimating productivity losses due to illness from a societal perspective rather than the friction-cost approach or the quality-adjusted life-year (QALY) approach as advocated by the US Panel on Cost-Effectiveness in Health and Medicine. However, although Liljas raises interesting issues, we feel that the incorporation of indirect costs estimated with the human capital–cost approach is not recommendable, especially for longer absence spells. [...]
Original language | English |
---|---|
Pages (from-to) | 563-566 |
Number of pages | 4 |
Journal | PharmacoEconomics |
Volume | 13 |
Issue number | 5 |
DOIs |
|
Publication status | Published - May 1998 |